t(11;14) does not predict long-term survival in myeloma [2]

Leukemia

Volumn 19, Issue 6, 2005, Pages 1078-1079

  Chang, Hong ^a,b   Qi, X Y ^a,b   Stewart, A K ^c  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN D1; IMMUNOGLOBULIN HEAVY CHAIN;

AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER MORTALITY; CANCER SURVIVAL; CHROMOSOME 13Q; CHROMOSOME DELETION; CHROMOSOME TRANSLOCATION; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; LETTER; MULTIPLE MYELOMA; PRIORITY JOURNAL; PROGNOSIS; ADULT; CHROMOSOME 11; CHROMOSOME 14; GENE TRANSLOCATION; GENETICS; MIDDLE AGED; MORTALITY; PREDICTION AND FORECASTING;

ADULT; CHROMOSOMES, HUMAN, PAIR 11; CHROMOSOMES, HUMAN, PAIR 14; HUMANS; MIDDLE AGED; MULTIPLE MYELOMA; PREDICTIVE VALUE OF TESTS; TRANSLOCATION, GENETIC;

EID: 20844434654     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2403744     Document Type: Letter

References (8)

1. Bergsagel PL, Kuehl WM. Chromosome translocations in multiple myeloma. Oncogene 2001; 20: 5611-5622.
2. Avet-Loiseau H, Li JY, Facon T, Brigaudeau C, Morineau N, Maloisel F et al. High incidence of translocations t(11;14)(q13;q32) and t(4;14)(p16;q32) in patients with plasma cell malignancies. Cancer Res 1998; 58: 5640-5645.
3. Fonseca R, Blood EA, Oken MM, Kyle RA, Dewald GW, Bailey RJ et al. Myeloma and t(11;14)(q13;q32): evidence for a biologically defined unique subsets of patients. Blood 2002; 99: 3735-3741.
4. Moreau P, Facon T, Leleu X, Morineau N, Huyghe P, Harousseau JL et al. Recurrent 14q32 translocations determine the prognosis of multiple myeloma, especially in patients receiving intensive chemotherapy. Blood 2002; 100: 1579-1583.
5. Zojer N, Konigsberg R, Ackermann J, Fritz E, Dallinger S, Kromer E et al. Deletion of 13q14 remains an independent adverse prognostic variable in multiple myeloma despite its frequent detection by interphase fluorescence in situ hybridization. Blood 2000; 95: 1925-1930.
6. Fonseca R, Harrington D, Oken MM, Dewald GW, Bailey RJ, Van Wier SA et al. Biological and prognostic significance of interphase fluorescence in situ hybridization detection of chromosomalities (del13) in multiple myeloma: an Eastern Cooperative Oncology Group Study. Cancer Res 2002; 62: 715-720.
7. Facon T, Avet-Loiseau H, Guillerm G, Moreau P, Geneieve F, Zandecki M et al. Intergroupe Francophone du Myelome. Chromosome 13 abnormalities identified by FISH analysis and serum beta-2 microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy. Blood 2001; 97: 1566-1571.
8. Chang H, Li D, Zhuang L, Nie E, Bouman D, Stewart AK et al. Detection of chromosome 13q deletions and IgH translocations in patients with multiple myeloma by FISH: comparison with karyotype analysis. Leukemia lymphoma 2004; 45: 965-969.